Estradiol Valerate
FDA-approved product (injectable, injection), marketed as Delestrogen, Estradiol Valerate.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Atrophic Vaginitis
- Atrophy
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Dyspareunia
- Hypogonadism
- Menopause
- Menorrhagia
- Osteoporosis
- Postmenopausal atrophic vaginitis
- Postmenopausal osteoporosis
- Premature ovarian insufficiency
- Primary ovarian insufficiency
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Natural and semisynthetic estrogens, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis22.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Estradiol Valerate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women
NCT01126801 · start 2010-05
Registered record
- Registry ID
- NCT01126801
- Conditions
- Menopausal Depression
- Interventions
- Estradiol; Placebo control
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2010-05
- Completion
- 2011-02
- Enrolment
- 2
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMenopausal DepressionInterventionEstradiol; Placebo controlPhasePhase 2Registry statusTerminatedNatural Versus HRT Cycles in Frozen Embryo Replacement Treatment
NCT00843570 · start 2009-11
Registered record
- Registry ID
- NCT00843570
- Conditions
- Infertility
- Interventions
- Nafarelin acetate, Oestradiol Valerate, Progesterone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-11
- Completion
- 2013-05
- Enrolment
- 159
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertilityInterventionNafarelin acetate, Oestradiol Valerate, ProgesteronePhasePhase 4Registry statusCompletedOral Contraceptives and Body Mass Index
NCT01170390 · start 2009-09
Registered record
- Registry ID
- NCT01170390
- Conditions
- Body Weight; Contraceptive Usage
- Interventions
- All participants (Aviane); Portia; Aviane
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2011-12
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBody Weight; Contraceptive UsageInterventionAll participants (Aviane); Portia; AvianePhasePhase 4Registry statusCompletedProgestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile
NCT01123538 · start 2008-12
Registered record
- Registry ID
- NCT01123538
- Conditions
- Pharmacogenomics; Systems Biology
- Interventions
- Progesterone; Chlormadinone acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2008-12
- Completion
- 2012-10
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPharmacogenomics; Systems BiologyInterventionProgesterone; Chlormadinone acetatePhasePhase 4Registry statusUnknownDrug Interaction - Oral Contraceptive
NCT00399685 · start 2006-12
Registered record
- Registry ID
- NCT00399685
- Conditions
- HIV Infections
- Interventions
- Ortho Tri-Cyclen LO; Ortho Cyclen; Ortho Cyclen + Efavirenz; Ortho Cyclen
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-12
- Completion
- 2007-08
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionOrtho Tri-Cyclen LO; Ortho Cyclen; Ortho Cyclen + Efavirenz; Ortho CyclenPhasePhase 1Registry statusCompletedEffect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route
NCT00701337 · start 2006-09
Registered record
- Registry ID
- NCT00701337
- Conditions
- Postmenopausal
- Interventions
- oestradiol; oestradiol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2010-01
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopausalInterventionoestradiol; oestradiolPhasePhase 4Registry statusCompletedStudy of Bleeding With Extended Administration of an Oral Contraceptive
NCT00338052 · start 2006-06
Registered record
- Registry ID
- NCT00338052
- Conditions
- Contraception
- Interventions
- Norethindrone 1 mg / ethinyl estradiol 20 mcg
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-06
- Completion
- 2007-05
- Enrolment
- 207
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionContraceptionInterventionNorethindrone 1 mg / ethinyl estradiol 20 mcgPhasePhase 2Registry statusCompletedHormonal Stimulation in IUI Treatment: Is Clomifen Combined With Ethinyl Estradiol Better, Worse or Equal to Menopur
NCT01569945 · start 2004-09
Registered record
- Registry ID
- NCT01569945
- Conditions
- Subfertility
- Interventions
- Clomifen, Ethinyl Estradiol; Menotropins
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-09
- Completion
- 2011-12
- Enrolment
- 371
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSubfertilityInterventionClomifen, Ethinyl Estradiol; MenotropinsPhaseNot applicableRegistry statusCompletedDocetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
NCT00083005 · start 2004-03
Registered record
- Registry ID
- NCT00083005
- Conditions
- Prostate Cancer
- Interventions
- docetaxel; estramustine phosphate sodium; thalidomide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-03
- Completion
- 2007-12
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventiondocetaxel; estramustine phosphate sodium; thalidomidePhasePhase 2Registry statusCompleted3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
NCT00310531 · start 2004-02
Registered record
- Registry ID
- NCT00310531
- Conditions
- Osteopenia
- Interventions
- Menostar (Estradiol, BAY86-5435); Raloxifene
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-02
- Completion
- 2007-06
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteopeniaInterventionMenostar (Estradiol, BAY86-5435); RaloxifenePhasePhase 3Registry statusCompletedEvaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.
NCT00261482 · start 2003-07
Registered record
- Registry ID
- NCT00261482
- Conditions
- Contraception; Female Contraception
- Interventions
- norelgestromin + ethinyl estradiol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-07
- Completion
- 2004-12
- Enrolment
- 778
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionContraception; Female ContraceptionInterventionnorelgestromin + ethinyl estradiolPhasePhase 4Registry statusCompletedA Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
NCT00218205 · start 2002-07
Registered record
- Registry ID
- NCT00218205
- Conditions
- Prostate Cancer
- Interventions
- Epirubicin; Estramustine Phosphate; Celecoxib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2002-07
- Completion
- 2006-06
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionEpirubicin; Estramustine Phosphate; CelecoxibPhasePhase 2Registry statusUnknownPostmenopausal Women Estrogen and Progesterone Infusion
NCT00455741 · start 2000-11
Registered record
- Registry ID
- NCT00455741
- Conditions
- Postmenopause; Aging
- Interventions
- Estradiol infusion; Progesterone infusion
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2000-11
- Completion
- 2015-08-22
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostmenopause; AgingInterventionEstradiol infusion; Progesterone infusionPhasePhase 1 / Phase 2Registry statusCompletedCombination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
NCT00014352 · start 2000-09
Registered record
- Registry ID
- NCT00014352
- Conditions
- Prostate Cancer; Thromboembolism
- Interventions
- docetaxel; doxorubicin hydrochloride; estramustine phosphate sodium; ketoconazole; warfarin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2000-09
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate Cancer; ThromboembolismInterventiondocetaxel; doxorubicin hydrochloride; estramustine phosphate sodium; ketoconazole +1 morePhasePhase 2Registry statusCompletedAssessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
NCT01425541 · start 2000-04
Registered record
- Registry ID
- NCT01425541
- Conditions
- Hyperandrogenemia; Polycystic Ovary Syndrome (PCOS)
- Interventions
- estrace; Progesterone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2000-04
- Completion
- 2025-08
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHyperandrogenemia; Polycystic Ovary Syndrome (PCOS)Interventionestrace; ProgesteronePhaseNot applicableRegistry statusUnknown